T. Pilgrim

Discipline

Economies et finances (1)

Type de document

Articles (8) Recensions (1)

Co-auteur

Date

Source

Mot-clé

Treatment (8) Patients (8) Patients (8) Myocardial infarction (7) Death (6) Human beings (6) Death (6) Drug-eluting stents (6) mort (6) sécurité (5) polymère (5) Prosthesis (5) Design (5) Design (5) risque (4) analyse (4) procès (4) Rates (4) Ci (Chinese poetry) (4) Thrombosis (4) Risk (4) Polymers (4) Analysis (4) Rates (4) danger (3) Trials (3) Respect (3) Reproduction (3) Rapamycin (3) thérapie (2)

Documents écrit par T. Pilgrim (8) | parle de T. Pilgrim (0)

Ultrathin-strut vs thin-strut drug-eluting stents for multi and single-stent lesions: A lesion-level subgroup analysis of 2 randomized trials.
J.D. Häner et al.
Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial.
J.F. Iglesias et al.
Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials.
T. Pilgrim et al.
Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
T. Pilgrim et al. (22 mars 2021)
Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction.
K.C. Koskinas et al. (13 avr. 2018)
Dual antiplatelet therapy for secondary prevention of coronary artery disease.
S. Degrauwe et al. (2017)
Repositionable Versus Balloon-Expandable Devices for Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis.
T. Pilgrim et al. (17 nov. 2016)
Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
R. Zbinden et al. (2016)